Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2565-2577

  Prasad, Shashi ^a   Cody, Virginia ^a   Saucier Sawyer, Jennifer K ^b   Fadel, Tarek R ^b   Edelson, Richard L ^a   Birchall, Martin A ^c   Hanlon, Douglas J ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University   (United States)

^c ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

^d YALE UNIVERSITY   (United States)

Author keywords

Antigen delivery; Dendritic cell; Immunotherapy; Molecular weight; Nanoparticles

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; INTERLEUKIN 10; INTERLEUKIN 2; POLYGLACTIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG RELEASE; DRUG STABILITY; FEMALE; FREEZE THAWING; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; MELANOMA; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COCULTURE TECHNIQUES; FEMALE; LACTIC ACID; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84866737579     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0787-4     Document Type: Article

References (41)

1. Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, et al. Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Rel. 118-126 (2010).
2. Thomas C, Gupta V, Ahsan F. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm. 2009;379:41-50.
3. Tel J, Lambeck AJA, Cruz LJ, Tacken PJ, de Vries IJM, Figdor CG. Human Plasmacytoid Dendritic Cells Phagocytose, Process, and Present Exogenous Particulate Antigen. J Immunol. 2010; 184:4276-83.
4. Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. Diclofenac sodium incorporated PLGA (50:50) microspheres: Formulation considerations and in vitro/in vivo evaluation. Int J Pharm. 2000;195:179-88.
5. Paolicelli P, Prego C, Sanchez A, Alonso MJ. Surface-modified PLGA-based nanoparticles that can efficiently associate and deliver virus-like particles. Nanomed. 2010;5:843-53.
6. Rajapaksa TE, Lo DD. Microencapsulation of vaccine antigens and adjuvants for mucosal targeting. Curr Immunol Rev. 2010;6:29-37.
7. Duan Y, Sun X, Gong T, Wang Q, Zhang Z. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo. J Mat Sci Mat Med. 2006;17:509-16.
8. Astaneh R, Erfan M, Moghimi H, Mobedi H. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J Pharm Sci. 2009;98:135-45.
9. Fu X, Ping Q, Gao Y. Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine APLGA microspheres. J Microencapsul. 2005;22:57-66.
10. Murillo M, Grillo MJ, Rene J, Marin CM, Barberan M, Blasco JM, et al. A Brucella ovis antigenic complex bearing (poly-e-caprolactone) microparticles confer protection against experimental brucellosis in mice. Vaccine. 2001;19:4099-106.
11. Ren JM, Zou QM, Wang FK, He Q, Chen W, Zen WK. PELA microspheres loaded H Pylori lysates and their mucosal immune response. World J Gastroenterol. 2002;8:1098-102.
12. Solbrig CM, Saucier-Sawyer JK, Cody V, Saltzman WM, Hanlon DJ. Polymer nanoparticles for immunotherapy from encapsulated tumor associated antigens and whole tumor cells. Mol Pharm. 2007;4:47-57.
13. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid)microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57:391-410.
14. Li XY, Kong XY, Shi S, Zheng XL, Guo G, Wei YQ, et al. Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol. 2008;8:89.
15. Marazuela EG, Prado N, Moro E, Fernandez-Garcia H, Villalba M, Rodriguez R. Intranasal vaccination with poly (lactide-co-glycolide) microparticles containing a peptide of T of Ole 1 prevents mice against sensitization. Clin Exp Allerg. 2008;38:520-8.
16. Zhou S, Liao X, Liang Z, Li X, Deng X, Li H. Preparation and characterization of biodegradable microspheres containing Hepatitis B surface antigen. Macromol Biosci. 2004;4:47-52.
17. Costantino HR, Langer R, Kilbanov KM. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J Pharm Sci. 1994;83:1662-9.
18. Fu K, Kilbanov KM, Langer R. Protein instability in controlledrelease systems. Nat Biotechnol. 2000;18:24-5.
19. Jaganathan KS, Singh P, Prabhakaran D, Mishra V, Vyas SP. Development of a single-dose stabilized poly (D, L lactic-coglycolic acid) microsphere-based vaccine against Hepatitis B. J Pharm Pharmacol. 2004;56:1243-50.
20. Ganguli MJK, Maiti S. Nanoparticles from cationic coploymers and DNA that are soluble and stable in common organic solvents. J Am Chem Soc. 2004;126:26-7.
21. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-702.
22. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569-80.
23. Johansen P, Gomez JMM, Gander B. Development of synthetic biodegradable microparticulate vaccines: A roller coaster story. Exp rev vaccines. 2007;6:471-4.
24. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opinion Immunol. 2005;17:163-9.
25. Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: An analysis of their potential in parenteral vaccination. Eur J Pharm and Biopharm. 2000;50:129-46.
26. Sesardic D, Dobbelaer R. European union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine. 2004;22:2452-6.
27. Mittal G, Sahana DK, Bhardwaj V, Ravi MNV. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release. 2007;119:77-85.
28. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly (d, l-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125:193-209.
29. Houchin M, Topp EM. Chemical degradation of peptides and proteins in PLGA: A review of reactions and mechanisms. J Pharm Sci. 2007;97:2395-404.
30. Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carr Syst. 2002;19:73-98.
31. Schwendeman SP, Costantino HR, Gupta RK, Tobio M, Chang AC, Alonso MJ, et al. Strategies for stabilizing tetanus toxoid toward the development of a single-does tetanus vaccine. Dev Biol Stand. 1996;87:293-306.
32. Kersten G, Donders D, Akkermans A, Beuvery EC. Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen. Vaccine. 1996;14:1627-32.
33. Tamber H, Johansen P, MerkleHP,Gander B. Formulation as pects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev. 2005;57:357-76.
34. Jelvehgari M, Valizadeh H, Rezapour M, Nokhodchi A. Control of encapsulation efficiency in polymeric microparticle system of tolmetin. Pharm Dev Technol. 2010;15:71-9.
35. Wang D, Robinson D, Kwona GS, Samuel J. Encapsulation of plasmid DNA in biodegradable poly(lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J Control Release. 1999;57:9-18.
36. Fogeda C, Brodina B, Frokjaera S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298:315-22.
37. Jaraswekin S, Prakongpan S, Bodmeier R. Effect of poly(lactideco- glycolide) molecular weight on the release of dexamethasone sodium phosphate from microparticles. J Microencapsul. 2007; 24:117-28.
38. Ravivarapu HB, Burton K, De Luca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm. 2000;50:263-70.
39. Mocellin S, Mandruzzato S, Zanovello P, Bronte V. Cancer rejection by the immune system: Forcing the check-points of tumor immune escape. Drug Discov Today: Dis Mech. 2005; 2:191-7.
40. Bharali DJ, Mousa SA, Thanavala Y. Micro-and nanoparticlebased vaccines for hepatitis B. Adv Exp Med Biol. 2007;601:415-21.
41. Elamanchili P, Lutsiak CME, Hamdy S, Diwan M, Samuel J. Pathogen-mimicking nanoparticles for vaccine delivery to dendritic cells. J Immunother. 2007;30:378-95.